Another aspect of the Aduhelm controversy emerged: its cost of $56,000 a patient per year. In the wake of weak sales of the product, Biogen cut the price to $28,200. But as the CRR report noted, ...

Biogen shares ... the cost will shift to patients, Vradenburg said. “Unless you are a very wealthy person, you are not going to get access to the drug,” he added. Aduhelm, given as a monthly ...

After months of debate about the validity of its phase 3 clinical trials for Alzheimer's therapy Aduhelm, Biogen has published the results in a peer-review journal, allowing physicians to look at ...

Expect to see Medicare grow slightly more expensive following last year’s unusual price drop. In January 2024, most U.S.

Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

Biogen posted fourth-quarter revenue and profit that topped expectations as its cost cuts showed progress and new products, including its breakthrough Alzheimer's treatment Leqembi, saw growth.